Efficacy of PJS-539 for Adult Patients With COVID-19.

Summary

The PJS-539 is a multicentre, phase 2, randomized, double-blind, placebo-controlled clinical trial to evaluate the effect of PJS-539 in the viral load of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Timeline

Start

2021-09-25

Primary completion

2022-02-03

Completion

2022-03-04

Drugs

Indications